cyrilzakka/clinical-trials huggingface dataset:
High-Resolution Solid-State Manometry of the Effect of Succinylcholine on Barrier Pressure

The lower esophageal sphincter（LES）plays a key role in preventing regurgitation and aspiration. The pressure of LES partly comes from striated muscles derived from the crural portion of the diaphragm. The effect of succinylcholine on esophagogastric junction during anesthesia induction is not clear. We conducted a prospective interventional study on the effect of succinylcholine on the barrier pressure (BrP) of the esophagogastric junction.

14 patients participated in the study. Propofol and succinylcholine were used for anesthesia induction. High-resolution solid-state manometry (HRM) was used to monitor the changes of the LES pressure and the intragastric pressure (IGP).The administration of propofol could significantly increase the LES pressure during end expiration and during inspiration. The application of succinylcholine had no effect on the LES pressure during end expiration, but significantly reduced the LES pressure during inspiration. Propofol had no effect on BrP. After the application of succinylcholine, BrP decreased significantly during inspiration.

Propofol significantly increased the LES pressure. Succinylcholine significantly reduced the pressure of LES and BrP during inspiration.

Eligibility Criteria:
Exclusion criteria：patients who classified as American Society of Anesthesiologists classification system (ASA) II were included. Patients were included in the study if they had on history of diabetes, pharynx and digestive diseases.

Exclusion criteria：currently pregnant or breastfeeding, a body mass index (BMI) over 30 kg/m2. All patients underwent preoperative preparation according to clinical routine and did not give preoperative drugs.
Care of Child's Hygiene From Zero to Two Years Old

This study aimed to identify the perceptions of family caregivers and professionals of the Family Health Strategy (FHS) for health care for children from 0 to 2 years, and actions on this issue developed by the FHS.

This study aimed to identify the perceptions of family caregivers and professionals of the Family Health Strategy (FHS) for health care for children from 0 to 2 years, and actions on this issue developed by the FHS. Chosen by a descriptive exploratory with a qualitative approach, consisting of 19 subjects while they were 9 professionals and 10 family caregivers. For data collection was used a semi-tour interview and for the treatment of empirical data, the technique of content analysis recommended by Bardin. For presentation and discussion of results the categories from the speech made the interviewers grouped as the possibility of confrontation between the speaches of the two groups, total of 6 categories: hygienist model: focus on personal hygiene, model medicocêntrico x extended care, environmental risk: the care with hygiene and socioeconomic conditions, family and life experience influence care with hygiene, process work x on caregiver perception of guidance received by the health service, link child / caregiver. The perceptions found in the discourse of professionals and caregivers showed that the biologically vision and focus on the body prevalent in health care, and that such care is still centered in the figure of the doctor because of the historical and cultural hegemony curative.

Eligibility Criteria:
Inclusion Criteria:

* children under two years old
* professional member of the healthcare team

Exclusion Criteria:

* caregivers who were not relatives
* children who had any physical impairment and/or mental
The Effect of High-intensity Laser Therapy in Patients With Carpal Tunnel Syndrome.

The aim of this study is to evaluate the effects of high intensity laser therapy (HILT) on pain, functional status, hand grip strength and median nerve cross-sectional area in ultrasonography in patients with carpal tunnel syndrome.

Patients who are admitted and diagnosed with carpal tunnel syndrome based on anamnesis, physical examination and electromyography are included in the study.

Eligibility Criteria:
Inclusion Criteria:

1. Electrophysiologically mild or moderate CTS
2. Patients who are literate and able to understand verbal instructions in our

Exclusion Criteria:

1. Diabetes
2. Systemic disorders that may affect treatment such as hypothyroidism, SLE, gout
3. History of polyneuropathy, cervical radiculopathy, brachial plexopathy
4. Injection for the carpal tunnel in the last 1 month
5. History of severe trauma, fracture, operation to both upper extremities at any time
6. Malignancy or history of malignancy
7. Renal failure
8. Peripheral or central nervous system diseases
9. Pregnancy
10. History of physical therapy program for the same hand wrist in the last months.
Tissue Destruction and Healing in Celiac Disease

The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particular, this study will examine the interactions between biological factors such as, intestinal epithelial cells, microbiota, immune system, genetics, and gluten and their effect on celiac disease clinical symptoms, and severity of tissue destruction and its ability to heal in individuals with celiac disease. Information collected in the study will help researchers to generate better resources to advance celiac disease patient care.

Celiac disease is an autoimmune enteropathy characterized by chronic inflammation of the small intestinal mucosa triggered by gluten uptake that occurs in genetically susceptible individuals carrying the specific class II human leucocyte antigens (HLA) DQ2 and DQ8 alleles. There is a spectrum in intestinal tissue damage associated with celiac disease. Some individuals develop inflammatory immunity in the absence of tissue damage, while others experience tissue damage ranging from partial to total villous atrophy. Persistent mucosal damage is associated with several severe complications, including lymphoproliferative malignancy and bone diseases. In addition, individuals with active celiac disease display a wide range of clinical symptoms, including metabolic defects that are not correlated to the degree of villous atrophy. Although much progress has been made in understanding celiac disease, major gaps remain in understanding biological mechanisms underlying inter-individual differences in clinical presentations and capacity to heal while maintaining a gluten-free diet.

Eligibility Criteria:
Inclusion Criteria:

Gluten challenge group:

1. Age 18 to 75 years old
2. Diagnosis of Celiac disease for at least 12 months by intestinal biopsy
3. Follow a strict gluten-free diet for at least the 12 consecutive months

Gluten de-challenge group:

1. Age 18 to 75 years old
2. Showing typical celiac disease symptoms
3. Not on a gluten-free diet

Control group:

1. Age 18 to 75 years old
2. Females who are not pregnant

Exclusion Criteria:

Gluten challenge group:

1. Diagnosis of any severe complication of celiac disease
2. Diagnosis of other chronic, active GI disease
3. Selective IgA deficiency
4. Severe reaction to gluten exposure
5. Any clinically significant diseases
6. History of significant substance or alcohol abuse
7. Pregnant or lactating
8. Diagnosis of blood clotting disorders

Gluten de-challenge group:

1. History of chronic inflammatory gastrointestinal disease
2. Gastrointestinal illness within the 4-week period prior to screening
3. History of lymphoproliferative disease
4. Uncontrolled blood clotting disorders
5. Any clinically significant diseases
6. History of significant substance or alcohol abuse

Control group:

1. Taking antibiotics, proton pump inhibitors, aspirin, or non-steroidal anti-inflammatory drugs
2. Known intestinal inflammation
3. Prior gastrointestinal surgery
4. Taking of antiplatelet agents or anticoagulants
5. Family history of celiac disease
Impact of Cataract Surgery on the Incidence and Progression of Dry Eye Disease

Relation between dry eye and cataract

Study the impact of cataract surgery on the incidence and progression of dry eye disease

Eligibility Criteria:
Inclusion Criteria:

* patients aged above 40-years old undergoing cataract surgery
* patients without dry eye disease
* patients with mild to moderate degree of dry eye disease Both gender, male and female

Exclusion Criteria:

* patients aged less 40-year old undergoing cataract surgery
* patients with severe degrees of dry eye disease
* patients with autoimmune disease
* patients with chronic blepharitis
TCM in the Treatment of Lung Adenocarcinoma

This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.

Lung adenocarcinoma (LUAD) is a type of non-small cell lung cancer (NSCLC) with a rapid disease progression and poor treatment effect. The LUAD patients have a short median survival time with 8-11 months. Up to now, chemotherapy is still the first-line treatment for LUAD. PC protocol (pemetrexed + cisplatin) is most commonly used, which is also recommended by NCCN guidelines. However, critical side effects have limited the application and efficacy. Patients will undergo poor quality of life, and the disease will progress rapidly. We still face the stern situation for the treatment of LUAD. It is urgent to develop new treatment and management strategies. Our previous study showed that jing-yuan-kang granule has certain curative effect on LUAD.

This is a multi-certers, randomized, controlled clinical trial to assess the efficacy and safety of Jing-yuan-kang granule in improving quality of life for LUAD patients. After a 2-week wash-out period, a total of 144 LUAD patients will be randomly assigned into experimental or control group with a ratio of 1:1. On the basis of that all the participants will receive PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with no other treatments for control group. The primary outcome is quality of life. The secondary outcomes include Karnofsky (KPS) scores, clinical symptoms, and change of tumor volume. Safety and adverse events will also be assessed.

Eligibility Criteria:
Inclusion Criteria:

* A confirmed diagnosis of LADC.
* Age ranges from17years to75years.
* A KPS score ≥40.
* Without radiotherapy, immunotherapy and targeted therapy.
* Without participanting in any other trial.
* With signed informed consent.

Exclusion Criteria:

* Pregnant, nursing or may become pregnant women.
* The patient has a history of allergy to any of the components of the intervention drug;
* Patients with severe liver and kidney dysfunction, cardiovascular and cerebrovascular diseases.
* Unconscious or unable to communicate normally.
* Patients with poor compliance.
Questionnaire About Individual's Insight/Awareness of Risk of Violence

The overall aim of this questionnaire is to gather the views of qualified clinicians on what factors contribute to an individual's insight or awareness into their own violent behaviours. The questionnaire will also explore what type of tool would be useful to develop for use in clinical practice to aid effective risk assessment and management. Brief demographic information will also be gathered.

Despite insight into violence being a factor regularly addressed by professionals in the assessment of future violence occurring research on this concept is sparse. Research instead tends to focus specifically on insight into violence specifically in relation to schizophrenia rather than more broadly in forensic and other clinical settings. What evidence there is suggests that developing an individual's insight or awareness of their own risk of violence is a key factor in reducing the likelihood of them engaging in further acts of violence. Being able to appropriately assess this is key and appears to currently be inconsistent between professionals.

In this study, therefore, a questionnaire will be disseminated to professionals working in secure care or a forensic community setting in order to gather their views on what factors contribute to an individual's insight or awareness into their own violent behaviours.

All clinicians/professionals who are currently employed and qualified as an Offender Manager, Offender Supervisor, Psychologist, Nurse, Social Worker, Occupational Therapist, Psychiatrist, Prison Officer currently working in a secure care or forensic community setting will be eligible to participate. Individuals with the appropriate qualifications working within private practice in the UK will also be eligible to participate. Those working outside the UK will not be eligible to participate.

Eligibility Criteria:
Inclusion Criteria:

* Employed as a qualified as a Psychologist, Nurse, Social Worker, Occupational Therapist, Psychiatrist, Prison Officer or Offender Manager currently working in a secure care or forensic community setting.

Exclusion Criteria:

* Those working solely in private practice outside of organisations and those who work outside the UK, are not eligible to participate
To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80 mg) manufactured at the Totowa, NJ facility relative to the formulation (80 mg) manufactured at the Wilson, NC facility in the fasted state.

Oxycodone hydrochloride (oxycodone) is a semi-synthetic opioid analgesic that is effective in the relief of moderate to severe malignant and non-malignant pain.

Eligibility Criteria:
Inclusion Criteria:

* Males and females aged 18 to 50, inclusive.
* Body weight ranging from 50 to 100 kg and a BMI ≥18 and ≤34 (kg/m2).
* Healthy and free of significant abnormal findings as determined by medical history, physical examination, vital signs, and ECG.
* Females of child-bearing potential must be using an adequate and reliable method of contraception.

Exclusion Criteria:

* Females who are pregnant or lactating.
* Any history of or current drug or alcohol abuse for 5 years.
* History of or any current conditions that might interfere with drug absorption, distribution, metabolism or excretion.
* Use of an opioid-containing medication in the past 30 days.
* History of known sensitivity to oxycodone, naltrexone, or related compounds.
* Any history of frequent nausea or emesis regardless of etiology.
* Any history of seizures or head trauma with current sequelae.
* Participation in a clinical drug study during the 30 days preceding the initial dose in this study.
* Any significant illness during the 30 days preceding the initial dose in this study.
* Use of any medication including thyroid hormone replacement therapy (hormonal contraception is allowed), vitamins, herbal, and/or mineral supplements, during the 7 days preceding the initial dose.
* Refusal to abstain from food for 4 hours following administration of the study drugs and to abstain from caffeine or xanthine entirely during each confinement.
* Consumption of alcoholic beverages within forty-eight (48) hours of initial study drug administration (Day 1) or anytime following initial study drug administration.
* History of smoking or use of nicotine products within 45 days of study drug administration or a positive urine cotinine test.
* Blood or blood products donated within 30 days prior to administration of the study drugs or anytime during the study, except as required by this protocol.
* Positive results for urine drug screen or alcohol screen at Check-in of each period, and HBsAg, HBsAb (unless immunized), anti-HCV.
* Positive Naloxone HCl challenge test.
* Presence of Gilbert's Syndrome or any known hepatobiliary abnormalities.
Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

RP-G28 is being investigated for treatment of moderate to severe lactose intolerance and its potential to improve the tolerance of lactose (dairy products).

Lactose intolerance is a common gastrointestinal (GI) disorder that develops in lactose maldigesters when consuming lactose or when lactose is added to a previously low-lactose diet. Lactose intolerance is characterized by one or more of the cardinal symptoms that follow the ingestion of lactose-containing foods. These symptoms include; abdominal pain, cramping, bloating, flatulence \[gas\] and diarrhea. As such, most lactose intolerant individuals avoid the ingestion of milk and dairy products, while others substitute non-lactose containing products in their diet. Currently, there are no approved treatments for this condition.

Based on the health implications from insufficient calcium intake over a lifetime, including increased risk of osteoporosis and hypertension, there is need in the medical community for a tolerable and convenient treatment that allows for all levels of milk and dairy product consumption in people suffering from mild to severe lactose intolerance.

Study Objective:

To access efficacy of two RP-G28 dosing regimes on symptoms related to lactose intolerance relative to placebo after 30 days of treatment. The 30 day post-treatment phase will further evaluate the treatment's potential to prolong relief from symptoms.

Study Design:

The participants will take about 60 days to complete the study. The study consists of 3 distinct phases: Screening, a 30-day Treatment Phase, and a 30-day Post-Treatment Phase (off study treatment observation period). A participant will need to visit the clinical only 6 times throughout the study.

Eligibility Criteria:
Inclusion/Exclusion Criteria:

* Female subjects must be non pregnant, and non lactating. Females of childbearing potential must use adequate birth control during study participation
* Medical history of intolerance to milk and other dairy products, and/or confirmed physician diagnosis of lactose intolerance.
* Must be free from any disorder known to be associated with gastrointestinal disease: irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), Celiac disease, diverticulitis, chronic constipation, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, small intestine bacterial overgrowth syndrome (SIBO), active gastric or duodenal ulcers, or history of severe ulcers.
* Must be nicotine free.
AYA OMGYES Sexual Health Study

The purpose of this study is to assess the impact of the web-based intervention OMGYES.com on sexual dysfunction in young adult (YA) female-bodied cancer survivors. This pilot trial seeks to evaluate the intervention's:

* feasibility
* acceptability
* appropriateness.

Researchers will utilize an active observation period to compare outcomes between those receiving the intervention immediately and those who haven't

Participants will:

* Complete online modules at home
* Visit the clinic every 5 weeks for questionnaires


Eligibility Criteria:
Inclusion Criteria:

* Age 18 to 40 years
* Diagnosis of cancer between the ages of 15 and 40
* Female genitalia, regardless of gender
* Diagnosed with sexual dysfunction
* Complete Remission and at least two months from a major treatment
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* Ability to participate in study modules and to respond to surveys
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients receiving other investigational agents
* Patients expected to be neutropenic or have a significantly high infection risk that would exclude them from vaginal penetration
* Patients who are unable complete the study intervention or surveys
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301EXT is an open-label, nonrandomized, phase 1 extension study of PSMA ADC administered IV in subjects with progressive CMPC that has progressed after prior taxane therapy. Subjects who have participated in PSMA ADC 1301 and who, in the opinion of the PI, are likely to benefit from continued treatment with PSMA ADC will be enrolled in PSMA ADC 1301EXT.


Eligibility Criteria:
Inclusion Criteria:

1. Subjects who have completed the PSMA ADC 1301 study and who, in the opinion of the investigator, have derived benefit from treatment with PSMA ADC.
2. A diagnosis of progressive, castration-resistant, metastatic prostate cancer.
3. Prior chemotherapy regimens, one of which contains taxane.
4. Eastern Cooperative Oncology Group status of 0 or 1

Exclusion Criteria:

1. Clinically significant cardiac disease or severe debilitation pulmonary disease
2. Evidence of an active infection requiring ongoing antibiotic therapy
3. History of drug and/or alcohol abuse
Distal Protection Combined With PTCA in AMI Patients

The primary objective is to evaluate if use of the AngioGuard™ XP improves myocardial reperfusion after PTCA as assessed by ST segment resolution at the end of PTCA.

This is a prospective, randomized, multicenter trial. Patients will be randomized either to be treated by PTCA only or in combination with the An-gioGuard™ XP device. The patients will be followed for six-months post-procedure.

Eligibility Criteria:
Inclusion Criteria:

* Acute myocardial infarction \< 12 hours with ST segment elevation \> 2 mm in at least 2 contiguous leads;
* Clinical indication of primary PTCA;
* De novo or restenotic lesions in native coronary vessel, single vessel treatment only;
* Target lesion stenosis is \> 80% (by visual estimation).

Exclusion Criteria:

* Patient has unprotected left main coronary disease with \> 50% stenosis in case left coronary artery is treated;
* Patient has an ostial target lesion;
* Killip class \> 3.
Investigation of Marginal Bone Loss in Implants with Different Surface Properties and Geometric Designs: a Retrospective Clinical Study

Purpose: The aim of this study was to investigate the influence of surface characteristics and geometric design on marginal bone loss and bone quality in dental implants.

Materials and Methods: A total of 378 implants from 114 patients were evaluated in this study using panoramic and periapical radiographs. Implants were categorized into 19 subgroups according to the jaw where they were placed, length, diameter, surface preparation, type of prosthetic superstructure, and neck design. Radiological evaluations were conducted based on radiographs obtained at the time of implant placement and 3 months after prosthetic loading. After obtaining measurements of marginal bone loss and fractal analysis data, the significance of differences between groups was statistically evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Implants with a minimum length of 8 mm
* Implants with a minimum diameter of 3.5 mm
* Availability of panoramic and periapical radiographs at T0 (immediately after surgery) and T1 (3 months after prosthetic loading).

Exclusion Criteria:

* Presence of a systemic condition hindering dental implant treatment and routine check-ups
* History of regular alcohol/tobacco use
* Presence of severe parafunctional habits (bruxism, etc.)
* Prior grafting procedures before dental implant placement
* Implant failure